Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2015 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Reports Improved Progression-Free Survival Results With Sacituzumab Govitecan in Triple-Negative Breast Cancer

BOSTON, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that patients with metastatic triple-negative breast cancer (TNBC) lived for a median of seven months without...
November 09, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Sacituzumab Govitecan Is Synergistic With Chemotherapeutics That Target Cell Division in Triple-Negative Breast Cancer

BOSTON, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today reported that new preclinical data for sacituzumab govitecan, the Company's lead antibody-drug conjugate (ADC) for solid...
November 04, 2015 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces First Quarter Fiscal 2016 Results and Clinical Program Developments

MORRIS PLAINS, N.J., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today reported financial results for the first quarter ended September 30, 2015. The Company also highlighted...
October 29, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2016 Financial Results

MORRIS PLAINS, N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2015 at...
October 19, 2015 14:35 ET | Source: Immunomedics, Inc.

Immunomedics Reports Durable Responses in Patients With Advanced Solid Cancers After Therapy With Sacituzumab Govitecan

SAN DIEGO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), produced...
September 08, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Reports Interim Phase 2 Results With Sacituzumab Govitecan in Lung Cancers

DENVER, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), continues to...
September 02, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Upcoming Investor Conferences

MORRIS PLAINS, N.J., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that the Company will be speaking at a Hematology/Oncology Panel at Wells Fargo Securities 2015...
August 19, 2015 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Fiscal 2015 Results and Clinical Program Developments

MORRIS PLAINS, N.J., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today reported financial results for the fourth quarter and fiscal year ended June 30, 2015. The Company also...
August 19, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Arthur S. Kirsch as Director

MORRIS PLAINS, N.J., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced the appointment of Arthur S. Kirsch, 63, to its Board of Directors. Mr. Kirsch has over 30 years...
August 18, 2015 07:00 ET | Source: Immunomedics, Inc.

Immunomedics Extends U.S. Patent Protection for Antibody-Drug Conjugate Program to 2033

MORRIS PLAINS, N.J., Aug. 18, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced the issuance of U.S. Patent No. 9,107,960 for a new patent family "Antibody-SN-38...